

Abstract BEAM Alliance

The growing risk of multi-drug resistant bacteria is a global public health crisis recognized by many governments; therefore, to combat the spread of resistant-bacteria and superbugs, new antibiotics, or alternative therapies must be developed. However, the financial attraction for R&D investment from large pharmaceutical companies is lacking, therefore, innovation in this therapeutic area is predominantly steered by small and medium pharma companies. To tackle the obstacle that superbugs present to society expeditiously, new policies and R&D incentives are needed to stimulate development in the EU. As an answer to this urgent need, we have formed the BEAM Alliance. The BEAM Alliance represents 50 European biopharmaceutical companies (small and medium size (SME)) from 12 European countries involved in developing innovative products to combat antimicrobial resistance in humans and beyond. The Working Group objective is to produce a new position paper regarding establishment of economic incentives in order to better sustain the innovation efforts of small and medium biopharmaceutical companies. The Working Group will collaborate with the existing community of stakeholders dedicated to implementing tangible strategies, including the EC DG SANTE, the UK AMR Review, WHO and the DRIVE-AB consortium. The BEAM Alliance Working Group should thus allow for expression of a unique and unprecedented opinion from the European SMEs perspective.

Domingo Gargallo-Viola (CSO), ABAC Therapeutics, SP
Lloyd Czaplewski (Founder & Director), Abgentis, UK
Fiona Marston (CEO), Absynth Biologics, UK
Edward Fang (CMO), Adenium Biotech, DK
Holger Schmoll (CFO), Aicuris, DE
Philippe Bordeau (CEO), Alaxia, FR
Nicholas Benedict (CEO), Allecra, DE
Marc Lemonnier (CEO), Antabio, FR
Morten Sommer (CSO), AntibioTx, DK
René Russo (CEO), Arsanis Biosciences, AT
Neil Miller (CSO), Auspherix, UK
Maek E. Jones (PM), Basilea, CH
Thierry Bernardi (CEO), BioFilm Control, FR
Marc Gitzinger (CEO), Bioversys, CH
Thomas Kapsner (CEO), Biovertis, AT
David Cook (CSO), Blueberry Therapeutics, UK
Mike Dawson (CEO), Cantab Anti-infectives, UK
Dominique Le Beller (CEO), Deinobiotics, FR
Bill Love (CEO), Destiny Pharma, Ltd., UK
David Williams (CEO), Discuva, UK
Xavier Duportet (CEO), Eligo Bioscience, FR
Lloyd Payne (SVP Anti-infectives, Operations), Evotec, UK-DE
Stefan Fischer (CEO), FAB Pharma, FR
Sir Anthony Coates (CSO), Helperby, UK
Blaz Petric, IMMT, SI
Anders Larsson (CSO), Immunsystem AB, SE
Alec Mclean (CEO), Lamellar Biomedical, UK
Hervé Affagard (CEO), Maat Pharma, FR
Miroslav Ravic (CEO), MGB Biopharma Limited, UK
Séverine Burdel (CEO), Mutabilis, FR
Stefano Donadio (CSO), Naicons (New Anti Infectives Consortium), IT
Martti Vaara (CEO), Northern Antibiotics Ltd, FI
Philippe Villain-Guillot (CEO), Nosopharm, FR

Dr. Deborah A. O'Neil (CSO), Novabiotics, UK
Thomas Pavie (Directeur « One Health »), OLMIX, FR
Jerome Gabard (CEO), Pherecydes, FR
Heather Fairhead (CEO), Phico Therapeutics, UK
Michael Altorfer (CEO), Polyphor Ltd, CH
Michael Mac Arthur (CSO), Procarta Biosystem, UK
Neil Murray (CEO), Redx Pharma, UK
Alessandro Pini (CSO), Setlance, IT
Jean-Christophe SERGERE (CEO), Setubio, FR
Timo Koopmans (COO), Synamp Pharmaceuticals, NL
Miguel Garcia (CEO), TechnoPhage SA , PT
Maxime Fontanié (CEO), Vibiosphen, FR
Mark Offerhaus (CEO), Microeos, NE
Michael Hafner, Nabriva Therapeutics, AT
Mike Westby (CEO), Centauri Therapeutics, UK
Andrew Shearer, Innovations Liaison Manager, Neem Biotech, UK